{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T01:48:43Z","timestamp":1700790523366},"reference-count":13,"publisher":"Universa BV","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AGEB"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:p>Background and study aims: Advanced liver disease frequently culminates in hepatic encephalopathy (HE), which can be classified as covert or overt HE, with subtle or clinically obvious changes respectively. 30-40% of patients with cirrhosis develop overt HE, which negatively affects the patients\u2019 quality of life. Next to lactulose, rifaximin-a has been prescribed as a second line therapy to treat and reduce the risk of recurrence of overt HE. In this study, we aimed to evaluate the effect of rifaximin-a therapy, both on the number of occurring infections and on the evolution in hospital admissions of patients with overt HE.\n\nPatients and methods: A total of 66 cirrhotic patients, treated for at least 6 months with rifaximin-a at AZ Maria Middelares, between October 1st 2014 and January 1st 2020, were included in the study analysis. Medical records of all patients were evaluated over a period of 6 months prior and after initiation of rifaximin-a therapy.\n\nResults: Data analysis revealed that the included cirrhotic patients were severely ill, with a mean model for end-stage liver disease (MELD) score of 21, and a median Child Pugh score of 11. Among these patients, rifaximin-a treatment significantly downgraded the total number of infections, with a main effect on respiratory infections. Furthermore, rifaximin-a therapy led to a significant decrease in HE-related, as well as in other liver-related hospital admissions.\n\nConclusions: This study confirms the potential value of rifaximin-a in reducing the number of developing infections and hospital admissions in a severely ill cirrhotic patient population.<\/jats:p>","DOI":"10.51821\/85.3.9524","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T12:02:44Z","timestamp":1668081764000},"page":"433-437","source":"Crossref","is-referenced-by-count":2,"title":["The impact of rifaximin on the hospital burden and infections in patients with hepatic encephalopathy: a retrospective observational study"],"prefix":"10.51821","volume":"85","author":[{"given":"J","family":"De Graeve","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Vanderstraeten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Delvaeye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"De Lepeleere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"De Somer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Van Steenkiste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27062","published-online":{"date-parts":[[2022,9]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"VILSTRUP H., AMODIO P., BAJAJ J., CORDOBA J., FERENCI P., MULLEN K.D. et al. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology, 2014, 60(2):715-735.","DOI":"10.1002\/hep.27210"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"ROSE C.F., AMODIO P., BAJAJ J.S., DHIMAN R.K., MONTAGNESE S., TAYLOR-ROBINSON S.D. et al. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. Journal of Hepatology, 2020, 73:1526-1547.","DOI":"10.1016\/j.jhep.2020.07.013"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"BUSTAMANTE J., RIMOLA A., VENTURA P-J., NAVASA M., CIRERA I., REGGIARDO V. et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. Journal of Hepatology, 1999, 30(5):P890-895.","DOI":"10.1016\/s0168-8278(99)80144-5"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"OEY R.C., BUCK L.E.M., ERLER N.S., VAN BUUREN H.R., DE MAN R. The efficacy and safety of rifaximin- : a 2-year observational study of overt hepatic encephalopathy. Therapeutic Advances in Gastroenterology, 2019, 12:1-10.","DOI":"10.1177\/1756284819858256"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"ORR J.G., CURRIE C.J., BERNI E., GOEL A., MORIARTY K.J., SINHA A. et al. The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin. Liver International, 2016, 36:1295-1303.","DOI":"10.1111\/liv.13111"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"BASS N.M., MULLEN K.D., SANYAL A., POORDAD F., NEFF G., LEEVY C.B. et al. Rifaximin Treatment in Hepatic Encephalopathy. N Engl J Med, 2010, 362(12):1071-1081.","DOI":"10.1056\/nejmoa0907893"},{"key":"ref6","unstructured":"ALI B., ZAIDI Y.A., ALAM A., ANJUM H.S. Efficacy of rifaximin in prevention of recurrence of hepatic encephalopathy in patients with cirrhosis of liver. J Coll Physicians Surg Pak, 2014, 24:269-73."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"KIMER N., KRAG A., MOLLER S., BENDTSEN F, GLUUD L.L. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther, 2014, 40(2):123-32.","DOI":"10.1111\/apt.12803"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"PUGH R.N., MURRAY-LYON I.M., DAWSON J.L., PIETRONI M.C., WILLIAMS R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg, 1973, 60:646-649.","DOI":"10.1002\/bjs.1800600817"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"PATIDAR K.R., BAJAJ J.S. Covert and overt hepatic encephalopathy: diagnosis and management. Clin Gastroenterol Hepatol, 2015, 13:2048-2061.","DOI":"10.1016\/j.cgh.2015.06.039"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"CHRISTENSEN E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores \u2013 where are we and where should we go? J Hepatol, 2004, 41:344-50.","DOI":"10.1016\/j.jhep.2004.06.005"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"SALEHI S., TRANAH T.H., LIM S., HEATON N., HENEGHAN M., ALUVIHARE V. et al. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list. Aliment Parmacol Ther., 2019, 50:435-441.","DOI":"10.1111\/apt.15326"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"HUDSON M., RADWAN A., DI MAGGIO P., CIPELLI R., RYDER S.D., DILLON J.F. et al. The impact of rifaximin- on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS). Frontline Gastroenterology, 2017, 0:1-9","DOI":"10.1136\/flgastro-2016-100792"}],"container-title":["Acta Gastro Enterologica Belgica"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T12:02:49Z","timestamp":1668081769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ageb.be\/ageb-journal\/ageb-volume\/ageb-article\/2031\/The%20impact%20of%20rifaximin%20on%20the%20hospital%20burden%20and%20infections%20in%20patients%20withhepatic%20encephalopathy:%20a%20retrospective%20observational%20study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":13,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,9]]},"published-print":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.51821\/85.3.9524","relation":{},"ISSN":["1784-3227"],"issn-type":[{"value":"1784-3227","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}